针灸加药物治疗气滞血瘀型肥胖症临床研究
|
摘要
1.目的:
随着社会的不断进步,人们生活水平的不断提高,肥胖人数急剧上升,肥胖不仅给生活带来诸多不便,影响身心健康甚剧,且易导致高脂血症、糖尿病、冠心病及脑卒中等并发症。由于肥胖症及其症的发病率逐年上升,已成为本世纪危害人类健康的全球性疾病。世界卫生组织在1997年明确宣布肥胖是一种疾病,并指出肥胖是当今全球侵蚀人类健康的流行病之一,是一个主要的公共卫生问题。肥胖与艾滋病、吸毒、酗酒已并列世界性四大医学社会问题。因此,积极防治肥胖已成为当前预防医学领域中一个刻不容缓的研究课题。
肥胖症目前西医主要透过行为和药物治疗,而治疗药物各有不同的作用特点,如食欲抑制剂和脂肪酶抑制剂等,长期服用均有明显副作用。中医药疗法在此方面已具明显优势,而针灸更是公认的一种“绿色”疗法,对肥胖症的临床治疗上获得满意的疗效,更具兼简、便、廉、效、安全、无毒副作用之优点,值得临床更深入的研究探讨与推广。
在进行本研究之前收集了许多有关肥胖症的文献资料,加上临床中的观察,发现目前台湾的肥胖症的证型中,以「气滞血瘀」型为多。因此,拟以针灸结合桃核承气汤来治疗「气滞血瘀」型的肥胖症。针灸具有疏通经络的功效,桃核承气汤《伤寒论》在临床上则用于治疗多种血瘀疾病,具有活血化瘀,清热泻下的功能,再依体质证型,予以疏肝理气之药治疗肥胖症。本课题针对女性运用针灸加药物治疗「气滞血瘀」型的肥胖症的作用,进行严密的观察论证,以探求其改善肥胖症的机制。本研究旨在观察单纯性肥胖者针刺减重效应,以体重、腰围、臀围、血脂代谢的变化及治疗结束后复胖之观察评估,来揭示针刺减肥的机理,探寻针刺减重的最佳适应症,并藉此研究过程,建立患者健康的生活习惯,提高减重动机,有效预防肥胖症。
2.方法:
根据诊断标准选择病患,将60例气滞血瘀型的肥胖症患者,以随机单盲的方式,将研究对象分为以下三组:
A组:电针合并中药制剂治疗组20例
B组:单纯电针刺激治疗组20例
C组:单纯中药制剂治疗组20例
编入A及B组者,每周定期接受三次电针刺激,每次30分钟共8周;编入为A及C组者每周看诊取药一次,每天三次饭后服用,七天份之药。
取穴:临证治疗以任脉和脾、胃经经穴为主穴,根据其脂肪堆积部位的不同,随症进行取穴。在腹部穴位、脂肪堆积较多处以电针机行电流持续刺激,所有穴位留针30分钟,加远红外线照射腹部。每周治疗三次,间隔1～2日针刺1次,一个月为一疗程,需连续治疗二个疗程。治疗疗程结束后,每个月至少回诊一次,连续观察三至六个月。减肥中药制剂:桃核承气汤(《伤寒论》)9克。每日三次,每次3克,于饭后温开水送服。
观察指标:肥胖指针(包括体重、脂肪百分率(F%)、体重指数、腰围、臀围、腰臀比);血脂检查(包括三酸甘油酯(TG)、总胆固醇(TC)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C));空腹血糖(GLU)。
本实验研究数据采用SPSS12.0 for Windows中文版软件处理,以描述性统计、成对样本t检定与oneway-anova作变异数同构型检测方法,P-value 0.05以下表示有显着差异性。再以Tukey HSD法作事后多重比较检定。
3.结果:
(1)肥胖症患者A、B、C三组的体重下降疗效比较上:
A组采用针药合并治疗,体重下降至少5公斤,达到显效的有12人(60%);体重下降至少3公斤而未达5公斤,达到有效的有7人(35%);体重下降少于3公斤,未达到疗效的有1人(5%)。B组采用电针治疗,体重下降至少5公斤以上,达到显效的有8人(40%);体重下降至少3公斤而未达5公斤,达到有效的有10人(50%);体重下降少于3公斤,未达到疗效的有2人(10%)。C组采用药物治疗,体重下降至少5公斤,达到显效的有5人(25%);体重下降至少3公斤而未达5公斤,达到有效的有8人(40%);体重下降少于3公斤,未达到疗效的有7人(35%)。A、B、C三组的体重下降疗效的总有效率达83.3%。
(2)肥胖症患者A、B、C三组的腰围下降疗效比较上:
A组采用针药合并治疗,腰围下降至少8公分以上,达到显效的有7人(35%);腰围下降至少4公分以上,达到有效的有12人(60%);腰围下降在4公分以下,未达到疗效的有1人(5%)。B组采用电针治疗,腰围下降至少8公分以上,达到显效的有5人(25%);腰围下降至少4公分以上,达到有效的有13人(65%);腰围下降在4公分以下,未达到疗效的有2人(10%)。C组采用药物治疗,腰围下降至少8公分以上,达到显效的有2人(10%);腰围下降至少4公分以上,达到有效的有12人(60%);腰围下降在4公分以下,未达到疗效的有6人(30%)。A、B、C三组的腰围下降疗效的总有效率达85%。
(3)肥胖症患者A、B、C三组的体重指数(BMI)下降疗效比较上:
A组采用针药合并治疗,BMI下降≥4,达到显效的有3人(15%);BMI下降＜4~≥2,达到有效的有16人(80%);BMI下降＜2,未达到疗效的有1人(5%)。B组采用电针治疗,BMI下降≥4,达到显效的有2人(10%);BMI下降＜4~≥2,达到有效的有16人(80%);BMI下降＜2,未达到疗效的有2人(10%)。C组采用药物治疗,BMI下降≥4,达到显效的有1人(5%);BMI下降＜4~≥2,达到有效的有12人(60%);BMI下降＜2,未达到疗效的有7人(35%)。A、B、C三组的体重指数(BMI)下降疗效的总有效率达83.3%。
(4)肥胖症患者A、B、C三组经成对样本T检定分析后发现,结论如下:
A、B、C三组治疗前后体重经成对样本T检定后发现,显着性为0.000,故拒绝HO:治疗前后体重无差异之虚无假设,可知治疗前后体重有差异,且均有显着下降。
(5)肥胖症患者A、B、C三组经成对样本T检定分析后发现,结论如下:
A、B、C三组治疗前后腰围经成对样本T检定后发现,显着性为0.000,故拒绝HO:治疗前后腰围无差异之虚无假设,可知治疗前后腰围有差异,且均有显着下降。
(6)肥胖症患者A、B、C三组经成对样本T检定分析后发现,结论如下:
A、B、C三组治疗前后臀围经成对样本T检定后发现,显着性为0.000,故拒绝HO:治疗前后臀围无差异之虚无假设,可知治疗前后臀围有差异,且均有显着下降。
(7)肥胖症患者A、B、C三组经成对样本T检定分析后发现,结论如下:
A、B、C三组治疗前后腰臀比(WHR)经成对样本T检定后发现,显着性为0.000,故拒绝HO:治疗前后腰臀比(WHR)无差异之虚无假设,可知治疗前后腰臀比(WHR)有差异,且均有显着下降。
(8)肥胖症患者A、B、C三组经成对样本T检定分析后发现,结论如下:
A、B、C三组治疗前后体重指数(BMI)经成对样本T检定后发现,显着性为0.000,故拒绝HO:治疗前后体重指数(BMI)无差异之虚无假设,可知治疗前后体重指数(BMI)有差异,且均有显着下降。
(9)肥胖症患者A、B、C三组经成对样本T检定分析后发现,结论如下:
A、B、C三组治疗前后脂肪百分比(F%)经成对样本T检定后发现,显着性为0.000,故拒绝HO:治疗前后脂肪百分比(F%)无差异之虚无假设,可知治疗前后脂肪百分比(F%)有差异,且均有显着下降。
(10)肥胖症患者A、B、C三组经成对样本T检定分析后发现,结论如下:
A、B、C三组治疗前后总胆固醇经成对样本T检定后发现,显着性为0.000,故拒绝HO:治疗前后总胆固醇无差异之虚无假设,可知治疗前后总胆固醇有差异,且均有显着下降。
(11)肥胖症患者A、B、C三组经成对样本T检定分析后发现,结论如下:
A、B、C三组治疗前后三酸甘油酯经成对样本T检定后发现,显着性为0.000,故拒绝HO:治疗前后三酸甘油酯无差异之虚无假设,可知治疗前后总胆固醇有差异,且均有显着下降。
(12)肥胖症患者A、B、C三组经成对样本T检定分析后发现,结论如下:
A、B、C三组治疗前后高密度脂蛋白经成对样本T检定后发现,显着性为0.000,故拒绝HO:治疗前后高密度脂蛋白无差异之虚无假设,可知治疗前后高密度脂蛋白有差异,且均有显着升高。
(13)肥胖症患者A、B、C三组经成对样本T检定分析后发现,结论如下:
A、B、C三组治疗前后低密度脂蛋白经成对样本T检定后发现,显着性为0.000,故拒绝HO:治疗前后低密度脂蛋白无差异之虚无假设,可知治疗前后低密度脂蛋白有差异,且均有显着下降。
(14)肥胖症患者A、B、C三组经成对样本T检定分析后发现,结论如下:
A、B、C三组治疗前后血醣经成对样本T检定后发现,显着性为0.000,故拒绝HO:治疗前后血醣无差异之虚无假设,可知治疗前后血醣有差异,且均有显着下降。
4.结论:
(1)在「体重差0-8」的变数下,A组与C组之显着性皆小于显着水准0.05,故可得知A组与C组之体重下降平均差异很显着,且因A组与C组的差为正数,可推论A组治疗方法可能优于C组;A组体重下降平均数为5.60(kg),达显效之标准;B组体重下降平均数为4.49(kg),达有效之标准;C组体重下降平均数为3.82(kg),达有效之标准。故利用电针合并中药制剂治疗是最安全、有效、经济的减肥方法之一。
(2)在「腰围差0-8」的变数下,A组与C组之显着性皆小于显着水准0.05,故可得知A组与C组之腰围差治疗平均差异很显着,且因A组与C组的差为正数,可推论A组治疗方法可能优于C组;A组腰围下降平均数为7.73(cm),达有效之标准;B组腰围下降平均数为5.88(cm),达有效之标准;C组腰围下降平均数为5.10(cm),达有效之标准。
(3)在「臀围差0-8」的变数下,A组与C组之显着性皆小于显着水准0.05,故可得知A组与C组之臀围差治疗平均差异很显着,且因A组与C组的差为正数,可推论A组治疗方法可能优于C组;
(4)在「T.C.差」的变量下,A组与C组之显着性皆小于显着水准0.05,故可得知A组与C组之总胆固醇差治疗平均差异很显着,且因A组与C组的差为正数,可推论A组治疗方法可能优于C组。
(5)根据实验文献报导,肥胖的程度越重,出现高脂血症的机率越大,平均总胆固醇、中性脂肪、低密度脂蛋白的浓度增加,高密度脂蛋白的浓度减少,这种现象青年肥胖患者比老年肥胖患者表现得更明显。成人肥胖患者体重减少,其脂质代谢也得到改善。
(6)腹围对肥胖的影响:反映肥胖程度以及腹部脂肪堆积的指标如体重指数(BMI)、腰围(WC)和腰臀比(WHR)与腹内脂肪面积呈显着正相关,尤以腰围WC的相关性最好。因此,这些指标也常被用来预测高血压、高脂血症、冠心病等相关疾病的发病危险性。此次实验统计三组之腰围、臀围在治疗前与治疗后相比较之下,皆有显着差异,每一组接受治疗后明显下降。三组之腰臀比在治疗前与治疗后相比较之下,皆有显着差异,每一组接受治疗后明显下降。
(7)本次临床研究发现电针合并中药制剂治疗、单纯电针刺激治疗或单纯中药制剂治疗肥胖症都可达到满意的减重疗效。更印证减轻体重能有效治疗肥胖及其延伸的相关慢性代谢性疾病,并取得了良好的临床治疗效果。但减重后的体重反弹在肥胖治疗中较多存在,严重影响了肥胖患者减重的积极性与意愿,也使人们普遍意识到防止减重后的体重反弹是比减重本身更困难的一件事情。应深入探讨减重后体重反弹的病因机制将有利于寻找防止体重反弹的治疗策略。
(8)对于肥胖患者来说,因为针灸是通过激发自身的调节机制来调整肥胖机体紊乱的内分泌及能量代谢功能的,从而使长期疗效有所保证,并可改善种种并发症。由于认知调节系统的存在,饮食控制和运动都难以坚持;而药物、手术又有副作用。相比之下,针灸则具有很大的优势:如无需一定的适应症;无毒副作用;美体塑身也可接受;可长期治疗等。同时针灸还具有简单、经济、安全等特点。故已为广大患者所接受。
(9)瘀血内生是肥胖合并症的关键。选用《伤寒论》桃核承气汤泻热逐瘀,治疗气滞血虚型的肥胖症患者,在本研究实验中亦取得明显疗效。
减重已是全民运动,更是一个必须从小即应长期监控的过程,希望肥胖症的临床研究,能为病患寻找出更有效及副作用少的减重治疗方式,减少肥胖症对身体所带来的危害,并进而能有效维持减重、促进健康。
Objective:
At present, the incidence of obesity goes up year after year. Traditional Chinese Medicine has evident predominance in curing it. Acupuncture, as a safe therapeutics, has good curative effect in clinic. This research will observe the effect of acupuncture and Peach Kernel Decoction (Taohe Chengqi Tang) for Ordering the Qi in curng qi stagnation and blood stasis syndrome of obesity. Methods:
Divide 60 patients chosen according to the diagnosis standard into three groups:
Group A: Electroacupuncture (EA) and Chinese Medicine, 20 cases
Group B: Electroacupuncture, 20 cases
Group C: Chinese Medicine, 20 cases
Acupoints: Choose acupoints of the Ren Meridian, the Spleen Meridian and the Stomach Meridian as the main points, and then change the points according to the fat parts.
Observing object: obesity exponential (including weight, Fat%, weight exponential, waistline, stern line, WHR); blood fat (including TG, TC, HDL-C, LDL-C, GLU). Results:
(1) The descending effect of weight of the three groups:
Group A: The obvious effect number is 12 (60%) whose weight goes down at least 5 kg; the effect number is 7 (35%) whose weight goes down at least 3 kg; the inefficacious number is 1 (5%) whose weight goes down less than 3 kg.Group B: The obvious effect number is 8 (40%) whose weight goes down at least 5 kg; the effect number is 10 (50%) whose weight goes down at least 3 kg; the inefficacious number is 2 (10%) whose weight goes down less than 3 kg. Group C: The obvious effect number is 5 (25%) whose weight goes down at least 5 kg; the effect number is 8 (40%) whose weight goes down at least 3 kg; the inefficacious number is 7 (35%) whose weight goes down less than 3 kg.The general effect rate of weight is 83.3% of the three groups.
(2) The descending effect of waistline of the three groups:
Group A: The obvious effect number is 7 (35%) whose waistline goes down at least 8 centimeters; the effect number is 12 (60%) whose waistline goes down at least 4 centimeters; the inefficacious number is 1 (5%) whose waistline goes down less than 4 centimeters.Group B: The obvious effect number is 5 (25%) whose waistline goes down at least 8 centimeters; the effect number is 13 (65%) whose waistline goes down at least 4 centimeters; the inefficacious number is 2 (10%) whose waistline goes down less than 4 centimeters.Group C: The obvious effect number is 2 (10%) whose waistline goes down at least 8 centimeters; the effect number is 12 (60%) whose waistline goes down at least 4 centimeters; the inefficacious number is 6 (30%) whose waistline goes down less than 4 centimeters.The general effect rate of waistline is 85% of the three groups.
(3) The descending effect of BMI of the three groups:
Group A: The obvious effect number is 3 (15%) whose BMI goes down more than 4; the effect number is 16 (80%) whose BMI goes down more than 2; the inefficacious number is 1 (5%) whose BMI goes down less than 2.Group B: The obvious effect number is 2 (10%) whose BMI goes down more than 4; the effect number is 16 (80%) whose BMI goes down more than 2; the inefficacious number is 2 (10%) whose BMI goes down less than 2.Group C: The obvious effect number is 1 (5%) whose BMI goes down more than 4; the effect number is 12 (60%) whose BMI goes down more than 2; the inefficacious number is 7 (35%) whose BMI goes down less than 2.The general effect rate of BMI is 83.3% of the three groups.
(4) Compared with the weight before and after treatment of group A、B and C, we can find there are differences which are obvious decline.
(5)Compared with the waistline before and after treatment of group A、B and C, we can find there are differences which are obvious decline.
(6)Compared with the stern line before and after treatment of group A、B and C, we can find there are differences which are obvious decline.
(7)Compared with the WHR before and after treatment of group A、B and C, we can find there are differences which are obvious decline.
(8)Compared with the BMI before and after treatment of group A、B and C, we can find there are differences which are obvious decline.
(9)Compared with the F% before and after treatment of group A、B and C, we can find there are differences which are obvious decline.
(10)Compared with the TC before and after treatment of group A、B and C, we can find there are differences which are obvious decline.
(11)DCompared with the TG before and after treatment of group A、B and C, we can find there are differences which are obvious decline.
(12)Compared with the HDL-C before and after treatment of group A、B and C, we can find there are differences which are obvious decline.
(13)Compared with the LDL-C before and after treatment of group A、B and C, we can find there are differences which are obvious decline.
(14)Compared with the GLU before and after treatment of group A、B and C, we can find there are differences which are obvious decline.
Conclusion:
(1) The average differences of weight descending between group A and group C, and the effect of group A is better than group C. The average of weight descending of group A is 5.6 kg, which is to the standard of obvious effect; the average of weight descending of group B is 4.49 kg, which is to the standard of effect; the average of weight descending of group C is 3.82 kg, which is to the standard of effect. So, EA and Chinese Medicine is one of the most effective, the most safe and the most economical methods.
(2)The average differences of waistline descending between group A and group C, and the effect of group A is better than group C. The average of weight descending of group A is 7.73 cm, which is to the standard of obvious effect; the average of weight descending of group B is 5.88 cm, which is to the standard of effect; the average of weight descending of group C is 5.10 cm, which is to the standard of effect. So, EA and Chinese Medicine is one of the most effective, the safest and the most economical methods.
(3) The average differences of stern line descending between group A and group C, and the effect of group A is better than group C.
(4) The average differences of TC descending between group A and group C, and the effect of group A is better than group C.
This research finds that EA and Chinese Medicine, EA, or Chinese Medicine has good effect in curing obesity. Because medicine has side-effects, acupuncture is the best choice. Also, acupuncture is so easy, economical, and safe that most people like it. Blood stasis of endogenesis is the key point of obesity symptom. Peach Kernel Decoction (Taohe Chengqi Tang) can rush heat down and expel stasis, and has good effect in curing qi stagnation and blood stasis syndrome of obesity.
随着社会的不断进步,人们生活水平的不断提高,肥胖人数急剧上升,肥胖不仅给生活带来诸多不便,影响身心健康甚剧,且易导致高脂血症、糖尿病、冠心病及脑卒中等并发症。由于肥胖症及其症的发病率逐年上升,已成为本世纪危害人类健康的全球性疾病。世界卫生组织在1997年明确宣布肥胖是一种疾病,并指出肥胖是当今全球侵蚀人类健康的流行病之一,是一个主要的公共卫生问题。肥胖与艾滋病、吸毒、酗酒已并列世界性四大医学社会问题。因此,积极防治肥胖已成为当前预防医学领域中一个刻不容缓的研究课题。
肥胖症目前西医主要透过行为和药物治疗,而治疗药物各有不同的作用特点,如食欲抑制剂和脂肪酶抑制剂等,长期服用均有明显副作用。中医药疗法在此方面已具明显优势,而针灸更是公认的一种“绿色”疗法,对肥胖症的临床治疗上获得满意的疗效,更具兼简、便、廉、效、安全、无毒副作用之优点,值得临床更深入的研究探讨与推广。
在进行本研究之前收集了许多有关肥胖症的文献资料,加上临床中的观察,发现目前台湾的肥胖症的证型中,以「气滞血瘀」型为多。因此,拟以针灸结合桃核承气汤来治疗「气滞血瘀」型的肥胖症。针灸具有疏通经络的功效,桃核承气汤《伤寒论》在临床上则用于治疗多种血瘀疾病,具有活血化瘀,清热泻下的功能,再依体质证型,予以疏肝理气之药治疗肥胖症。本课题针对女性运用针灸加药物治疗「气滞血瘀」型的肥胖症的作用,进行严密的观察论证,以探求其改善肥胖症的机制。本研究旨在观察单纯性肥胖者针刺减重效应,以体重、腰围、臀围、血脂代谢的变化及治疗结束后复胖之观察评估,来揭示针刺减肥的机理,探寻针刺减重的最佳适应症,并藉此研究过程,建立患者健康的生活习惯,提高减重动机,有效预防肥胖症。
2.方法:
根据诊断标准选择病患,将60例气滞血瘀型的肥胖症患者,以随机单盲的方式,将研究对象分为以下三组:
A组:电针合并中药制剂治疗组20例
B组:单纯电针刺激治疗组20例
C组:单纯中药制剂治疗组20例
编入A及B组者,每周定期接受三次电针刺激,每次30分钟共8周;编入为A及C组者每周看诊取药一次,每天三次饭后服用,七天份之药。
取穴:临证治疗以任脉和脾、胃经经穴为主穴,根据其脂肪堆积部位的不同,随症进行取穴。在腹部穴位、脂肪堆积较多处以电针机行电流持续刺激,所有穴位留针30分钟,加远红外线照射腹部。每周治疗三次,间隔1～2日针刺1次,一个月为一疗程,需连续治疗二个疗程。治疗疗程结束后,每个月至少回诊一次,连续观察三至六个月。减肥中药制剂:桃核承气汤(《伤寒论》)9克。每日三次,每次3克,于饭后温开水送服。
观察指标:肥胖指针(包括体重、脂肪百分率(F%)、体重指数、腰围、臀围、腰臀比);血脂检查(包括三酸甘油酯(TG)、总胆固醇(TC)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C));空腹血糖(GLU)。
本实验研究数据采用SPSS12.0 for Windows中文版软件处理,以描述性统计、成对样本t检定与oneway-anova作变异数同构型检测方法,P-value 0.05以下表示有显着差异性。再以Tukey HSD法作事后多重比较检定。
3.结果:
(1)肥胖症患者A、B、C三组的体重下降疗效比较上:
A组采用针药合并治疗,体重下降至少5公斤,达到显效的有12人(60%);体重下降至少3公斤而未达5公斤,达到有效的有7人(35%);体重下降少于3公斤,未达到疗效的有1人(5%)。B组采用电针治疗,体重下降至少5公斤以上,达到显效的有8人(40%);体重下降至少3公斤而未达5公斤,达到有效的有10人(50%);体重下降少于3公斤,未达到疗效的有2人(10%)。C组采用药物治疗,体重下降至少5公斤,达到显效的有5人(25%);体重下降至少3公斤而未达5公斤,达到有效的有8人(40%);体重下降少于3公斤,未达到疗效的有7人(35%)。A、B、C三组的体重下降疗效的总有效率达83.3%。
(2)肥胖症患者A、B、C三组的腰围下降疗效比较上:
A组采用针药合并治疗,腰围下降至少8公分以上,达到显效的有7人(35%);腰围下降至少4公分以上,达到有效的有12人(60%);腰围下降在4公分以下,未达到疗效的有1人(5%)。B组采用电针治疗,腰围下降至少8公分以上,达到显效的有5人(25%);腰围下降至少4公分以上,达到有效的有13人(65%);腰围下降在4公分以下,未达到疗效的有2人(10%)。C组采用药物治疗,腰围下降至少8公分以上,达到显效的有2人(10%);腰围下降至少4公分以上,达到有效的有12人(60%);腰围下降在4公分以下,未达到疗效的有6人(30%)。A、B、C三组的腰围下降疗效的总有效率达85%。
(3)肥胖症患者A、B、C三组的体重指数(BMI)下降疗效比较上:
A组采用针药合并治疗,BMI下降≥4,达到显效的有3人(15%);BMI下降＜4~≥2,达到有效的有16人(80%);BMI下降＜2,未达到疗效的有1人(5%)。B组采用电针治疗,BMI下降≥4,达到显效的有2人(10%);BMI下降＜4~≥2,达到有效的有16人(80%);BMI下降＜2,未达到疗效的有2人(10%)。C组采用药物治疗,BMI下降≥4,达到显效的有1人(5%);BMI下降＜4~≥2,达到有效的有12人(60%);BMI下降＜2,未达到疗效的有7人(35%)。A、B、C三组的体重指数(BMI)下降疗效的总有效率达83.3%。
(4)肥胖症患者A、B、C三组经成对样本T检定分析后发现,结论如下:
A、B、C三组治疗前后体重经成对样本T检定后发现,显着性为0.000,故拒绝HO:治疗前后体重无差异之虚无假设,可知治疗前后体重有差异,且均有显着下降。
(5)肥胖症患者A、B、C三组经成对样本T检定分析后发现,结论如下:
A、B、C三组治疗前后腰围经成对样本T检定后发现,显着性为0.000,故拒绝HO:治疗前后腰围无差异之虚无假设,可知治疗前后腰围有差异,且均有显着下降。
(6)肥胖症患者A、B、C三组经成对样本T检定分析后发现,结论如下:
A、B、C三组治疗前后臀围经成对样本T检定后发现,显着性为0.000,故拒绝HO:治疗前后臀围无差异之虚无假设,可知治疗前后臀围有差异,且均有显着下降。
(7)肥胖症患者A、B、C三组经成对样本T检定分析后发现,结论如下:
A、B、C三组治疗前后腰臀比(WHR)经成对样本T检定后发现,显着性为0.000,故拒绝HO:治疗前后腰臀比(WHR)无差异之虚无假设,可知治疗前后腰臀比(WHR)有差异,且均有显着下降。
(8)肥胖症患者A、B、C三组经成对样本T检定分析后发现,结论如下:
A、B、C三组治疗前后体重指数(BMI)经成对样本T检定后发现,显着性为0.000,故拒绝HO:治疗前后体重指数(BMI)无差异之虚无假设,可知治疗前后体重指数(BMI)有差异,且均有显着下降。
(9)肥胖症患者A、B、C三组经成对样本T检定分析后发现,结论如下:
A、B、C三组治疗前后脂肪百分比(F%)经成对样本T检定后发现,显着性为0.000,故拒绝HO:治疗前后脂肪百分比(F%)无差异之虚无假设,可知治疗前后脂肪百分比(F%)有差异,且均有显着下降。
(10)肥胖症患者A、B、C三组经成对样本T检定分析后发现,结论如下:
A、B、C三组治疗前后总胆固醇经成对样本T检定后发现,显着性为0.000,故拒绝HO:治疗前后总胆固醇无差异之虚无假设,可知治疗前后总胆固醇有差异,且均有显着下降。
(11)肥胖症患者A、B、C三组经成对样本T检定分析后发现,结论如下:
A、B、C三组治疗前后三酸甘油酯经成对样本T检定后发现,显着性为0.000,故拒绝HO:治疗前后三酸甘油酯无差异之虚无假设,可知治疗前后总胆固醇有差异,且均有显着下降。
(12)肥胖症患者A、B、C三组经成对样本T检定分析后发现,结论如下:
A、B、C三组治疗前后高密度脂蛋白经成对样本T检定后发现,显着性为0.000,故拒绝HO:治疗前后高密度脂蛋白无差异之虚无假设,可知治疗前后高密度脂蛋白有差异,且均有显着升高。
(13)肥胖症患者A、B、C三组经成对样本T检定分析后发现,结论如下:
A、B、C三组治疗前后低密度脂蛋白经成对样本T检定后发现,显着性为0.000,故拒绝HO:治疗前后低密度脂蛋白无差异之虚无假设,可知治疗前后低密度脂蛋白有差异,且均有显着下降。
(14)肥胖症患者A、B、C三组经成对样本T检定分析后发现,结论如下:
A、B、C三组治疗前后血醣经成对样本T检定后发现,显着性为0.000,故拒绝HO:治疗前后血醣无差异之虚无假设,可知治疗前后血醣有差异,且均有显着下降。
4.结论:
(1)在「体重差0-8」的变数下,A组与C组之显着性皆小于显着水准0.05,故可得知A组与C组之体重下降平均差异很显着,且因A组与C组的差为正数,可推论A组治疗方法可能优于C组;A组体重下降平均数为5.60(kg),达显效之标准;B组体重下降平均数为4.49(kg),达有效之标准;C组体重下降平均数为3.82(kg),达有效之标准。故利用电针合并中药制剂治疗是最安全、有效、经济的减肥方法之一。
(2)在「腰围差0-8」的变数下,A组与C组之显着性皆小于显着水准0.05,故可得知A组与C组之腰围差治疗平均差异很显着,且因A组与C组的差为正数,可推论A组治疗方法可能优于C组;A组腰围下降平均数为7.73(cm),达有效之标准;B组腰围下降平均数为5.88(cm),达有效之标准;C组腰围下降平均数为5.10(cm),达有效之标准。
(3)在「臀围差0-8」的变数下,A组与C组之显着性皆小于显着水准0.05,故可得知A组与C组之臀围差治疗平均差异很显着,且因A组与C组的差为正数,可推论A组治疗方法可能优于C组;
(4)在「T.C.差」的变量下,A组与C组之显着性皆小于显着水准0.05,故可得知A组与C组之总胆固醇差治疗平均差异很显着,且因A组与C组的差为正数,可推论A组治疗方法可能优于C组。
(5)根据实验文献报导,肥胖的程度越重,出现高脂血症的机率越大,平均总胆固醇、中性脂肪、低密度脂蛋白的浓度增加,高密度脂蛋白的浓度减少,这种现象青年肥胖患者比老年肥胖患者表现得更明显。成人肥胖患者体重减少,其脂质代谢也得到改善。
(6)腹围对肥胖的影响:反映肥胖程度以及腹部脂肪堆积的指标如体重指数(BMI)、腰围(WC)和腰臀比(WHR)与腹内脂肪面积呈显着正相关,尤以腰围WC的相关性最好。因此,这些指标也常被用来预测高血压、高脂血症、冠心病等相关疾病的发病危险性。此次实验统计三组之腰围、臀围在治疗前与治疗后相比较之下,皆有显着差异,每一组接受治疗后明显下降。三组之腰臀比在治疗前与治疗后相比较之下,皆有显着差异,每一组接受治疗后明显下降。
(7)本次临床研究发现电针合并中药制剂治疗、单纯电针刺激治疗或单纯中药制剂治疗肥胖症都可达到满意的减重疗效。更印证减轻体重能有效治疗肥胖及其延伸的相关慢性代谢性疾病,并取得了良好的临床治疗效果。但减重后的体重反弹在肥胖治疗中较多存在,严重影响了肥胖患者减重的积极性与意愿,也使人们普遍意识到防止减重后的体重反弹是比减重本身更困难的一件事情。应深入探讨减重后体重反弹的病因机制将有利于寻找防止体重反弹的治疗策略。
(8)对于肥胖患者来说,因为针灸是通过激发自身的调节机制来调整肥胖机体紊乱的内分泌及能量代谢功能的,从而使长期疗效有所保证,并可改善种种并发症。由于认知调节系统的存在,饮食控制和运动都难以坚持;而药物、手术又有副作用。相比之下,针灸则具有很大的优势:如无需一定的适应症;无毒副作用;美体塑身也可接受;可长期治疗等。同时针灸还具有简单、经济、安全等特点。故已为广大患者所接受。
(9)瘀血内生是肥胖合并症的关键。选用《伤寒论》桃核承气汤泻热逐瘀,治疗气滞血虚型的肥胖症患者,在本研究实验中亦取得明显疗效。
减重已是全民运动,更是一个必须从小即应长期监控的过程,希望肥胖症的临床研究,能为病患寻找出更有效及副作用少的减重治疗方式,减少肥胖症对身体所带来的危害,并进而能有效维持减重、促进健康。
Objective:
At present, the incidence of obesity goes up year after year. Traditional Chinese Medicine has evident predominance in curing it. Acupuncture, as a safe therapeutics, has good curative effect in clinic. This research will observe the effect of acupuncture and Peach Kernel Decoction (Taohe Chengqi Tang) for Ordering the Qi in curng qi stagnation and blood stasis syndrome of obesity. Methods:
Divide 60 patients chosen according to the diagnosis standard into three groups:
Group A: Electroacupuncture (EA) and Chinese Medicine, 20 cases
Group B: Electroacupuncture, 20 cases
Group C: Chinese Medicine, 20 cases
Acupoints: Choose acupoints of the Ren Meridian, the Spleen Meridian and the Stomach Meridian as the main points, and then change the points according to the fat parts.
Observing object: obesity exponential (including weight, Fat%, weight exponential, waistline, stern line, WHR); blood fat (including TG, TC, HDL-C, LDL-C, GLU). Results:
(1) The descending effect of weight of the three groups:
Group A: The obvious effect number is 12 (60%) whose weight goes down at least 5 kg; the effect number is 7 (35%) whose weight goes down at least 3 kg; the inefficacious number is 1 (5%) whose weight goes down less than 3 kg.Group B: The obvious effect number is 8 (40%) whose weight goes down at least 5 kg; the effect number is 10 (50%) whose weight goes down at least 3 kg; the inefficacious number is 2 (10%) whose weight goes down less than 3 kg. Group C: The obvious effect number is 5 (25%) whose weight goes down at least 5 kg; the effect number is 8 (40%) whose weight goes down at least 3 kg; the inefficacious number is 7 (35%) whose weight goes down less than 3 kg.The general effect rate of weight is 83.3% of the three groups.
(2) The descending effect of waistline of the three groups:
Group A: The obvious effect number is 7 (35%) whose waistline goes down at least 8 centimeters; the effect number is 12 (60%) whose waistline goes down at least 4 centimeters; the inefficacious number is 1 (5%) whose waistline goes down less than 4 centimeters.Group B: The obvious effect number is 5 (25%) whose waistline goes down at least 8 centimeters; the effect number is 13 (65%) whose waistline goes down at least 4 centimeters; the inefficacious number is 2 (10%) whose waistline goes down less than 4 centimeters.Group C: The obvious effect number is 2 (10%) whose waistline goes down at least 8 centimeters; the effect number is 12 (60%) whose waistline goes down at least 4 centimeters; the inefficacious number is 6 (30%) whose waistline goes down less than 4 centimeters.The general effect rate of waistline is 85% of the three groups.
(3) The descending effect of BMI of the three groups:
Group A: The obvious effect number is 3 (15%) whose BMI goes down more than 4; the effect number is 16 (80%) whose BMI goes down more than 2; the inefficacious number is 1 (5%) whose BMI goes down less than 2.Group B: The obvious effect number is 2 (10%) whose BMI goes down more than 4; the effect number is 16 (80%) whose BMI goes down more than 2; the inefficacious number is 2 (10%) whose BMI goes down less than 2.Group C: The obvious effect number is 1 (5%) whose BMI goes down more than 4; the effect number is 12 (60%) whose BMI goes down more than 2; the inefficacious number is 7 (35%) whose BMI goes down less than 2.The general effect rate of BMI is 83.3% of the three groups.
(4) Compared with the weight before and after treatment of group A、B and C, we can find there are differences which are obvious decline.
(5)Compared with the waistline before and after treatment of group A、B and C, we can find there are differences which are obvious decline.
(6)Compared with the stern line before and after treatment of group A、B and C, we can find there are differences which are obvious decline.
(7)Compared with the WHR before and after treatment of group A、B and C, we can find there are differences which are obvious decline.
(8)Compared with the BMI before and after treatment of group A、B and C, we can find there are differences which are obvious decline.
(9)Compared with the F% before and after treatment of group A、B and C, we can find there are differences which are obvious decline.
(10)Compared with the TC before and after treatment of group A、B and C, we can find there are differences which are obvious decline.
(11)DCompared with the TG before and after treatment of group A、B and C, we can find there are differences which are obvious decline.
(12)Compared with the HDL-C before and after treatment of group A、B and C, we can find there are differences which are obvious decline.
(13)Compared with the LDL-C before and after treatment of group A、B and C, we can find there are differences which are obvious decline.
(14)Compared with the GLU before and after treatment of group A、B and C, we can find there are differences which are obvious decline.
Conclusion:
(1) The average differences of weight descending between group A and group C, and the effect of group A is better than group C. The average of weight descending of group A is 5.6 kg, which is to the standard of obvious effect; the average of weight descending of group B is 4.49 kg, which is to the standard of effect; the average of weight descending of group C is 3.82 kg, which is to the standard of effect. So, EA and Chinese Medicine is one of the most effective, the most safe and the most economical methods.
(2)The average differences of waistline descending between group A and group C, and the effect of group A is better than group C. The average of weight descending of group A is 7.73 cm, which is to the standard of obvious effect; the average of weight descending of group B is 5.88 cm, which is to the standard of effect; the average of weight descending of group C is 5.10 cm, which is to the standard of effect. So, EA and Chinese Medicine is one of the most effective, the safest and the most economical methods.
(3) The average differences of stern line descending between group A and group C, and the effect of group A is better than group C.
(4) The average differences of TC descending between group A and group C, and the effect of group A is better than group C.
This research finds that EA and Chinese Medicine, EA, or Chinese Medicine has good effect in curing obesity. Because medicine has side-effects, acupuncture is the best choice. Also, acupuncture is so easy, economical, and safe that most people like it. Blood stasis of endogenesis is the key point of obesity symptom. Peach Kernel Decoction (Taohe Chengqi Tang) can rush heat down and expel stasis, and has good effect in curing qi stagnation and blood stasis syndrome of obesity.
引文
[1]Marette A:Mediators of cytokine-induced insulin resistance in obesity and otherinflammatory settings.Curt Opin Clin Nutr Metab Care 2002;5:377-383.
[2]中国成人超重和肥胖症预防与控制指南(J).营养学报,2004,26(1):1-4。
[3]施杞主编.现代中医药应用与研究大系.第15卷老年病科.上海中医药大学出版社,1995,p.2
[4]Reaven G:Banting lecture 1988:Role of insulin resistance in human disease,Diabetologia1988;30:1595-1607.
[5]Alberti KG,Zimmet PZ:Definition,diagnosis and classification of diabetes mellitus and itscomplications,Part 1:Diagnosis and classification of diabetes mellitus provisional report ofa WHO consultation,Diabetes Metab 1998;15:539-553.
[6]Ford ES,Giles WH,Dietz WH:Prevalence of the metabolic syndrome among US adults:findings from the third Naional Health and Nutrition examination survey.JAMA 2002;26:356-359.
[7]Das UN:Is metabolic syndrome X an inflammatory condition? Exp Biol Med 2002;221:989-997.
[8]Chuang SY,Chen CH,Tsai ST,et al:Clinical identification of the metabolic syndrome inKimen.Acta Cardiol Sin 2002:16-23.
[9]Haffiner S,Taegtmeyer H:Epidemic obesity and the metabolic syndrome.Circulation 2003;108:1541-1545.
[10]H ansen Be:The Metabolic syndrome X,Ann NY Acad Sci 1999:892:1-24.
[11]Himsworth HP:Diabetes mellitus:its differentiation into insulin sensitive and insulininsensitive types.Lancet 1936;1:127-130.
[12]Evans JL,Goldfine ID,Maddux,BA,et al:Oxidative stress and stress-activated signalingpathways:a unifying hypothesis of type 2 diabetes.Endocr Rev 2002;23:599-622.
[13]Bjorntorp P,Holm G,Rosmond R:Hypothalamic arousal,insulin resistance and type 2diabetes mellitus.Diabetes Metab 1999;16:373-383.
[14]Moller DE:New drug targets for type 2 diabetes and the metabolic syndrome.Nature 2002;414:821-827.
[15]Lin HZ,Yang SQ,Chuckaree C,et al:Metformin reverses fatty liver disease in obese,leptin-deficint mice.Nat Med 2000;6:998-1003
[16]Bodkin NL,Ortmeyer HK,Hansen BC:Long-term dietary restrictionin older-aged rhesusmonkeys:effects on insulin resistance.J Gerontol 1995;50:B142-B147.
[17]Chiu HC,Chang HY,Mau LW,Lee TK,Liu HW:Heiht,weight,and body mass index ofelderly person in Taiwan.J Gerontol.55A:M684-M690,2000.
[18]Foucan L,Hanley J,Deloumeaux J,Suissa S:Body mass index(BMI)and waistcircumference(We)as screening tools for cardiovascular risk factors in Guadeloupeanwomen.J Clini Epidemiol.55:990-996,2002.
[19]Sullivan DR:Cardiovascular risk in the Asia-Pacific region from a nutrition and metabolicpoint of view:visceral obesity.Asia Pacific J Clin Nutr.10(2):82-84,2001.
[20]行政院卫生署.国人肥胖定义及处理原则.2002.http://www.doh.gov.tw
[21]行政院卫生署.成人肥胖定义.2002.http://www.doh.gov.tw
[22]梁继权,肥胖症的临床评估,台大医院家庭医师继续教育系列讲座,2002;(32-6)。
[23]Turcato E,Bosello O,Francesco VD,Harris TB,Zoico E,et al:Waist circumference andabdominal sagittal diameter as surrogates of body far distribution in the elderly:their relation with cardiovascular risk factors.Int J Obes.24:1005-1010,2000.
[24]Sullivan DR:Cardiovascular risk in the Asia-Pacific region from a nutrition and metabolic point of view:visceral obesity.Asia Pacific J Clin Nutr.10(2):82-84,2001.
[25]Goodman-Gruen D,Barrett-Connor E:Sex differences in measures of body fat and body fat distribution in the elderly.Am J Epidemiol.143:898-906,1996.
[26]Wellens RI,Roche AE,Khamis HJ,Jackson AS,Pollock ML,Siervogel RM:Relationships between the body mass index and body composition.Obes Res.4:35-44,1996.
[27]Tanaka S,Togashi K,Rankinen T,Perusse L,Leon AS,Rao DC:Is adiposity at normal body weight relevant for cardiovascular disease risk? Int J Obes.26:176-183,2002
[28]Marinos Elia:Obesity in the Elderly Obes Res,2001:9:S244-S248.
[29]James R,Brulhart-Meynet M,Lehmann T,Golay A,Lipoprotein distribution and composition in obesity:their association with central adiposity.Int J Obes Relat Metab Disord. 1997; 21: 1115-20.
[30] Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitusin women. Ann Intern Med.1995; 122: 481-6.
[31] Despres J-P, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ.2002; 322: 716-20.
[32] Roland J, Thorpe, JR, Kenneth F, Ferraro, Aging, Obesity, and Mortality: Misplaced concern about obese older people? Research on Aging, Vol.26 No 1. January 2004: 108-129.
[33] Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: result ofAFCAPS / TexCAPS. JAMA. 279: 1615-1622,1998.
[34] Lewis SJ, Sack FM, Mitchell JS, East C, Glasser S, et al: Effect of pravastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) trial. J Am Coll Cardiol. 32: 140-146,1998.
[35] National Cholesterol Education Program (NCEP): Summary of the Second Report of theNational Cholesterol Education Program (NCEP) Expert Panel on Detection, Evalution and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 269: 3015-3023,1993.
[36] Drexel H, Amann FW, Beran J, Rentsch K, Candinas R, et al: Plasma triglycerides and threelipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation. 90: 2230-2235,1994.
[37] National Cholesterol Education Program (NCEP): Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection,Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).JAMA. 285: 2001.
[38] Burchfiel CM, Laws A, Benfante R, Goldberg RJ, Hwang LJ, et al: Combined effects ofHDL cholesterol, triglyceride, and total cholesterol concentration on 18-year risk of atherosclerotic disease. Circulation. 92: 1430-1436,1995.
[39] Krumholz HM, Seeman TE, Merrill SS, Mendes de Leon CF, Vaccarino V, et al: Lack of association between cholesterol and coronary heart disease mortality and morbidity andall-cause mortality in persons older than 70 years.JAMA.272:1335-1340,1994.
[40]Weverling-Rijnsburger AWE,Jonkers IJAM,Exel E,Gussekloo J,Westendorp RGJ:Highdensity vs low-density lipoprotein cholesterol as the risk factoe for coronary artry disease and stroke in old age.Arch Intern Med.163:1549-1554,2003.[41]Castelli WP:Lipids,risk factors and ischaemic heart disease Atherosclerosis.124:1-S9,1996.
[42]Burchfiel CM,Laws A,Benfante R,Goldberg RJ,Hwang LJ,et al:Combined effects of HDL cholesterol,triglyceride,and total cholesterol concentration on 18-year risk of atherosclerotic disease.Circulation.92:1430-1436,1995.
[43]Jeppesen J:Triglyceride concentration and ischemic heart disease:an eight-year follow-upin the Copenhagen Male Study.Circulation.97:1029-1036,1998
[44]行政院卫生署国民健康局.台湾地区高血压、高血糖、高血脂之盛行率调查报告,2003.
[45]行政院卫生署.国民营养状况变迁调查.1993-1996.
[46]Simons L,Friedlander Y,Simons J,McCallum J:Lipoprotein(a)is not associated withcoronary heart disease in the elderly:cross-sectional data from the Dubbo study.Atherosclerosis.99:87-95,1993.
[47]Knopp RH:Risk factors for coronary artery disease in women.Am J Cardiol.89:28E-35E,2002.
[48]Simon LA,Simons J,Friedlander Y,McCallum J:Cholesterol and other lipids predictcoronary heart disease and ischemic stroke in the elderly,but only in those below 70 yraes.Atherosclerosis.159:201-208,2001.
[49]Chou P,Shaw CK,Lai MY:Community-based study on the relationship between serumcholesterol / triglyceride and dietary habits / life styles in Pu-Li,Taiwan.Chin Med J (Taipei).52:155-160,1993.
[50]上海医科大学《实用内科学》编委会.实用内科学(M)第9版.北京:人民卫生出版社,1995.667-668。
[51]杨年红,胡虞志,黄耙.我国11城市儿童单纯性肥胖症调查及影响因素分析.同济医科大学学报,1999,28(5):394-396。
[52]王永炎.中医内科学(M)上海.上海科学技术出版社,1997.337。
[53]林应华.实脾轻身饮治疗单纯性肥胖症的临床研究(J).中国中西医结合脾胃杂志,1999,7(2):110-111。
[54]宋咏梅,宋昌红.肥胖体型者辨证论治规律初探(J).甘肃中医院学报,1997,14(3):8-9
[55]廖清奎.近代儿科疾病的诊断和治疗.肥胖症(M).成都:四川科技出版社,1988.8
[56]崔鸿峥.单纯性肥胖症的传统康复治疗(J).锦州医学院学报,1996.17(6):26-27
[57]熊磊.儿童单纯性肥胖之我见(J).云南中医学院学报,1997.20(2):32-36
[58]何浩,张玉亮,李海梅.胖子减肥胶囊治疗单纯性肥胖症的临床观察(J).第一军医大学学报,1999,19(4):44-45
[59]张淑亭,宋福生,李玉英等.降脂减肥健美饮治疗高脂肥胖症18例观察(J).河北中医,1994,16(4):12-13
[60]日本原桃介.肥胖症的汉方治疗(J).国外医学.中医中药分册1994,15(2):96-97
[61]朴联友,刘颖,张学丽.飞腾八法治疗单纯性肥胖(J).中国中医药讯息杂志,2002,9(7):5
[62]刘志诚,孙风岷,胡葵.针灸为主治疗单纯性肥胖患者的临床研究(J).上海针灸杂志,1997,16(1):6-8
[63]阙方旭,任爱华.扶元温肾法治疗单纯性肥胖症54例(J).中国民间疗法,1998,6(6):5
[64]李春生,陈可冀,冯晋光等.消补减肥片治疗老年单纯性肥胖病的研究(J).光明中医杂志,1994,9(3):18-20
[65]张文学.消胖丸治疗单纯性肥胖症286例临床观察(J).中医函授通讯,1999,18(2):21-22
[66]翁维良.中医治疗单纯性肥胖44例疗效观察(J).中医杂志,1988,40(1):29。
[67]孙庆培.肥胖症的中医治疗概况(J).中医杂志,1990.(5):53
[68]孟丽娟,孟鶱鹏,高秀丽.电针辨证治疗女性单纯性肥胖180例(J).中国临床康复,2002,6(23):35-36
[69]王红玉.针刺治疗单纯性肥胖病60例临床疗效观察.针灸临床杂志,2001,17(4):27-28
[70]张忠志,马峰峻,马野.耳针治疗418例单纯肥胖的效果观察(J).黑龙江医药 科学,2001,24(4):75-76
[71]Wozniak P,Oszukowski P,Stachowiak G,et al.The Effectiveness of low-caloric Diet orDiet with ACupuncture Treatment in Obese peri-and post-menopausal[J].Women GinekoiPol,2003,74(2):102.
[72]顾悦善,郑学良,崔述贵等.王不留行耳压减肥473例临床观察.中医杂志,1988,29(4):12
[73]何玲,江婵娟耳穴贴压在临床减肥中的应用(J).陕西中医学院学报,2003,26(3):37-38
[74]曹春,马逸.穴位埋线治疗肥胖症24例临床观察(J).中国针灸,1995,2(增刊):137
[75]杨福霞.穴位埋线治疗单纯性肥胖症的临床研究(J).中国针灸,2005,25(4):237-239
[76]许姿妙.穴位埋线治疗肥胖症100例临床观察.中国针灸,2002,22(2):95-96
[77]王国明,李丽霞,宋永强等.穴位埋线治疗单纯性肥胖症60例疗效观察.中国针灸,2001,21(7):395-406
[78]邹秋英.针刺治疗肥胖症100例疗效观察.河北中医,2001,23(7):530-531
[79]曲惠卿.针刺对肥胖病患者肾上腺皮质功能及血脂含量的影响.中国针灸,1994,14(1):1-2
[80]高洪生.针刺治疗单纯性肥胖症68例.陕西中医,2000,21(5):223-224
[81]金传,杨金山.电针与推拿并用治疗单纯性肥胖的临床观察29例(J).中级药学报,2003,31(3):16
[82]Taubes G.AS Obesity Rates Rise,Experts Struggle to Explain Why.Science.1998;280:B67-B68.
[83]Jung RT,Obesity as a disease.Br.Med.Bull 1997;53:307-21.
[84]Bjointorp P.Obesity.The Lancet.1997;350(9075):423-426.
[85]Wilding J.Science,medicine and the furture:Obesity treatment.BMJ.1997;315(7114):997-1000.
[86]翁维良.肥胖病学.知音出版社.台北,1996:4-5。
[87]Zang Y.Positional cloning of the mouse obese gene and it human homologue.Nature 1994;372:425-431.
[88]Dhurandhar NV.Association of anovirus infection with human obesity.Obesity Research1997;5:464-469.
[89]Atkinson RL.Use of Drugs in the treatment of obesity.Annu.Rev.Nutr.1997;17:383-403.
[90]Halaas JL.Weight-reducing effects of the plasma protein encoded by the obese gene.Science 1995;269(5223):543-546.
[91]Steven BH,Andrew SG.Recombinant Leptin for Weight Loss in Obese and Lean Adults.JAMA 1999;282:1568-1575.
[92]张介宾.张氏类经.新文丰出版社,1984:462-463。
[93]任应秋.素问今译.启业书局.台北.,1988:495。
[94]任应秋.素问今译.启业书局.台北,1988:524。
[95]任应秋.素问今译.启业书局.台北,1988:85。
[96]张景岳.景岳全书.人民卫生出版社,1985:86-88。
[97]翁维良.肥胖冠心病人心功能观察.全国第三届肥胖病研究学术会议,1991:25-29
[98]朱震亨.丹溪心法要.山东科技技术出版社,1985:1-14
[99]翁维良.实用中西结合肥胖病学.知音出版社,台北,1990:11
[100]胡绍文.单纯性肥胖证的预防.北京中医,1994增刊:2。
[101]陈敏先.降脂减肥片治疗肥胖证之临床观察.上海中医药杂志,1992,(5)1:41
[102]耿新华.减肥灵治疗893例肥胖证疗效观察.北京中医,1994增刊:102
[103]贾宝鹏.北京市34000人肥胖病调查.北京中医,1994增刊:197
[104]喜多岛修也.防风通圣散,防己黄耆汤力.肥胖证12文寸节反影响.日本东洋医学会志,1993;43(5):63
[105]徐如唐译.防风通圣散减肥作用的基础研究(日).国外医学.中医中药分册,1995:17(3):33
[106]宫本尚.和治医药会志,1994,11(4):400
[107]河上征治.肥胖病汉方治疗.现代东洋医学,1994,15(4):22-25
[108]陆静译.针刺治疗肥胖之研究.国外医学.中医中药分册,1994;16(4):49
[109]戚东焰译.采取一种新型耳针治疗病理性肥胖(英).国外医学.中医中药分册,1993:15(1):53。
[110]Lei ZP.Treatment of 42 cases of obesity with acupuncture.Journal of Traditional ChineseMesicine.1998;8(2):125-126.
[111]Xu B,Fei JZ.Clinical observation of the weight-reducing effect ear acupuncture in 350cases of obesity.Journal of Traditional Chinese Mesicine.1985;5(2):87-88.
[112]Hung MH,Yang RC,Hu SH.Preliminary results of triple therapy for obesity.1996;20(9):830-836.
[113]Shafshak TS.Electroacupuncture & exercise in body weight reduction and theirapplication in rehabilitating with knee osteoarthritis.American Journal of CchineseMedicine.1995;23(1):15-25.
[114]李国达.针灸治疗肥胖症近十年状况.针灸临床杂志,2000;(6):51-53。
[115]Vogrluk VG,Uglanova TM,Vogrluk MV.Role of reflexotherapy in the complex treatmentof neuroendocrine obesity.Terapevticheskii Arkhiv.1985;57(10):97-100.
[116]刘建英译.电针刺激肥胖证影响之研究.国外医学.中医中药分册,1994;16(1):59
[117]刘志诚.针刺减肥与植物神经功能的关系.中国康复医学杂志,1989;4(6):30
[118]Shiraishi T,Onoe M,Kojima T,Sameshima Y.Effects of auricular stimulation on feedingrtatedhypothalamic neuronal activity in normal and obesity rats.Brin Research Bulletin.1995;36(2):141-8.
[119]Liu ZC,Sun FM,Li J.Study of the theraprutic effect of acupuncture onl 134 cases ofsimple obesity.Int J Clin Acup.1998;2(2):6-8.
[120]Liu Z.et al.The good effects of acupuncture on digestive function in the patients suffering from simple obesity with stomach-heat accumlation.The Second World Congress ofMedical Acupuncture & Natural Medicine;1991:88
[121]Faust S.For an updated acupuncture.Revue Medicale de Bruxelles.1998;19(4):A290-A295.
[122]Sun FM,Liu ZC.Effect of acupuncture on energy metabolism in simple obesity.Int J ClinAcup.1997;8(2):123-128.
[123]刘志诚.针刺减肥的临床观察及其降低脂肪的研究.中国康复医学杂志,1990;5(3):110。
[124]Sun FM,Liu ZC,et al.Effect of acupuncture weight reduction on water metabolism.Int J Clin Acup.1999;10(1):1-7。
[125]刘志诚,孙凤鸣,韩燕等.针刺治疗单纯性肥胖症的实验研究.针刺研究,1998;23(1):69-75。
[2]中国成人超重和肥胖症预防与控制指南(J).营养学报,2004,26(1):1-4。
[3]施杞主编.现代中医药应用与研究大系.第15卷老年病科.上海中医药大学出版社,1995,p.2
[4]Reaven G:Banting lecture 1988:Role of insulin resistance in human disease,Diabetologia1988;30:1595-1607.
[5]Alberti KG,Zimmet PZ:Definition,diagnosis and classification of diabetes mellitus and itscomplications,Part 1:Diagnosis and classification of diabetes mellitus provisional report ofa WHO consultation,Diabetes Metab 1998;15:539-553.
[6]Ford ES,Giles WH,Dietz WH:Prevalence of the metabolic syndrome among US adults:findings from the third Naional Health and Nutrition examination survey.JAMA 2002;26:356-359.
[7]Das UN:Is metabolic syndrome X an inflammatory condition? Exp Biol Med 2002;221:989-997.
[8]Chuang SY,Chen CH,Tsai ST,et al:Clinical identification of the metabolic syndrome inKimen.Acta Cardiol Sin 2002:16-23.
[9]Haffiner S,Taegtmeyer H:Epidemic obesity and the metabolic syndrome.Circulation 2003;108:1541-1545.
[10]H ansen Be:The Metabolic syndrome X,Ann NY Acad Sci 1999:892:1-24.
[11]Himsworth HP:Diabetes mellitus:its differentiation into insulin sensitive and insulininsensitive types.Lancet 1936;1:127-130.
[12]Evans JL,Goldfine ID,Maddux,BA,et al:Oxidative stress and stress-activated signalingpathways:a unifying hypothesis of type 2 diabetes.Endocr Rev 2002;23:599-622.
[13]Bjorntorp P,Holm G,Rosmond R:Hypothalamic arousal,insulin resistance and type 2diabetes mellitus.Diabetes Metab 1999;16:373-383.
[14]Moller DE:New drug targets for type 2 diabetes and the metabolic syndrome.Nature 2002;414:821-827.
[15]Lin HZ,Yang SQ,Chuckaree C,et al:Metformin reverses fatty liver disease in obese,leptin-deficint mice.Nat Med 2000;6:998-1003
[16]Bodkin NL,Ortmeyer HK,Hansen BC:Long-term dietary restrictionin older-aged rhesusmonkeys:effects on insulin resistance.J Gerontol 1995;50:B142-B147.
[17]Chiu HC,Chang HY,Mau LW,Lee TK,Liu HW:Heiht,weight,and body mass index ofelderly person in Taiwan.J Gerontol.55A:M684-M690,2000.
[18]Foucan L,Hanley J,Deloumeaux J,Suissa S:Body mass index(BMI)and waistcircumference(We)as screening tools for cardiovascular risk factors in Guadeloupeanwomen.J Clini Epidemiol.55:990-996,2002.
[19]Sullivan DR:Cardiovascular risk in the Asia-Pacific region from a nutrition and metabolicpoint of view:visceral obesity.Asia Pacific J Clin Nutr.10(2):82-84,2001.
[20]行政院卫生署.国人肥胖定义及处理原则.2002.http://www.doh.gov.tw
[21]行政院卫生署.成人肥胖定义.2002.http://www.doh.gov.tw
[22]梁继权,肥胖症的临床评估,台大医院家庭医师继续教育系列讲座,2002;(32-6)。
[23]Turcato E,Bosello O,Francesco VD,Harris TB,Zoico E,et al:Waist circumference andabdominal sagittal diameter as surrogates of body far distribution in the elderly:their relation with cardiovascular risk factors.Int J Obes.24:1005-1010,2000.
[24]Sullivan DR:Cardiovascular risk in the Asia-Pacific region from a nutrition and metabolic point of view:visceral obesity.Asia Pacific J Clin Nutr.10(2):82-84,2001.
[25]Goodman-Gruen D,Barrett-Connor E:Sex differences in measures of body fat and body fat distribution in the elderly.Am J Epidemiol.143:898-906,1996.
[26]Wellens RI,Roche AE,Khamis HJ,Jackson AS,Pollock ML,Siervogel RM:Relationships between the body mass index and body composition.Obes Res.4:35-44,1996.
[27]Tanaka S,Togashi K,Rankinen T,Perusse L,Leon AS,Rao DC:Is adiposity at normal body weight relevant for cardiovascular disease risk? Int J Obes.26:176-183,2002
[28]Marinos Elia:Obesity in the Elderly Obes Res,2001:9:S244-S248.
[29]James R,Brulhart-Meynet M,Lehmann T,Golay A,Lipoprotein distribution and composition in obesity:their association with central adiposity.Int J Obes Relat Metab Disord. 1997; 21: 1115-20.
[30] Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitusin women. Ann Intern Med.1995; 122: 481-6.
[31] Despres J-P, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ.2002; 322: 716-20.
[32] Roland J, Thorpe, JR, Kenneth F, Ferraro, Aging, Obesity, and Mortality: Misplaced concern about obese older people? Research on Aging, Vol.26 No 1. January 2004: 108-129.
[33] Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: result ofAFCAPS / TexCAPS. JAMA. 279: 1615-1622,1998.
[34] Lewis SJ, Sack FM, Mitchell JS, East C, Glasser S, et al: Effect of pravastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) trial. J Am Coll Cardiol. 32: 140-146,1998.
[35] National Cholesterol Education Program (NCEP): Summary of the Second Report of theNational Cholesterol Education Program (NCEP) Expert Panel on Detection, Evalution and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 269: 3015-3023,1993.
[36] Drexel H, Amann FW, Beran J, Rentsch K, Candinas R, et al: Plasma triglycerides and threelipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation. 90: 2230-2235,1994.
[37] National Cholesterol Education Program (NCEP): Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection,Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).JAMA. 285: 2001.
[38] Burchfiel CM, Laws A, Benfante R, Goldberg RJ, Hwang LJ, et al: Combined effects ofHDL cholesterol, triglyceride, and total cholesterol concentration on 18-year risk of atherosclerotic disease. Circulation. 92: 1430-1436,1995.
[39] Krumholz HM, Seeman TE, Merrill SS, Mendes de Leon CF, Vaccarino V, et al: Lack of association between cholesterol and coronary heart disease mortality and morbidity andall-cause mortality in persons older than 70 years.JAMA.272:1335-1340,1994.
[40]Weverling-Rijnsburger AWE,Jonkers IJAM,Exel E,Gussekloo J,Westendorp RGJ:Highdensity vs low-density lipoprotein cholesterol as the risk factoe for coronary artry disease and stroke in old age.Arch Intern Med.163:1549-1554,2003.[41]Castelli WP:Lipids,risk factors and ischaemic heart disease Atherosclerosis.124:1-S9,1996.
[42]Burchfiel CM,Laws A,Benfante R,Goldberg RJ,Hwang LJ,et al:Combined effects of HDL cholesterol,triglyceride,and total cholesterol concentration on 18-year risk of atherosclerotic disease.Circulation.92:1430-1436,1995.
[43]Jeppesen J:Triglyceride concentration and ischemic heart disease:an eight-year follow-upin the Copenhagen Male Study.Circulation.97:1029-1036,1998
[44]行政院卫生署国民健康局.台湾地区高血压、高血糖、高血脂之盛行率调查报告,2003.
[45]行政院卫生署.国民营养状况变迁调查.1993-1996.
[46]Simons L,Friedlander Y,Simons J,McCallum J:Lipoprotein(a)is not associated withcoronary heart disease in the elderly:cross-sectional data from the Dubbo study.Atherosclerosis.99:87-95,1993.
[47]Knopp RH:Risk factors for coronary artery disease in women.Am J Cardiol.89:28E-35E,2002.
[48]Simon LA,Simons J,Friedlander Y,McCallum J:Cholesterol and other lipids predictcoronary heart disease and ischemic stroke in the elderly,but only in those below 70 yraes.Atherosclerosis.159:201-208,2001.
[49]Chou P,Shaw CK,Lai MY:Community-based study on the relationship between serumcholesterol / triglyceride and dietary habits / life styles in Pu-Li,Taiwan.Chin Med J (Taipei).52:155-160,1993.
[50]上海医科大学《实用内科学》编委会.实用内科学(M)第9版.北京:人民卫生出版社,1995.667-668。
[51]杨年红,胡虞志,黄耙.我国11城市儿童单纯性肥胖症调查及影响因素分析.同济医科大学学报,1999,28(5):394-396。
[52]王永炎.中医内科学(M)上海.上海科学技术出版社,1997.337。
[53]林应华.实脾轻身饮治疗单纯性肥胖症的临床研究(J).中国中西医结合脾胃杂志,1999,7(2):110-111。
[54]宋咏梅,宋昌红.肥胖体型者辨证论治规律初探(J).甘肃中医院学报,1997,14(3):8-9
[55]廖清奎.近代儿科疾病的诊断和治疗.肥胖症(M).成都:四川科技出版社,1988.8
[56]崔鸿峥.单纯性肥胖症的传统康复治疗(J).锦州医学院学报,1996.17(6):26-27
[57]熊磊.儿童单纯性肥胖之我见(J).云南中医学院学报,1997.20(2):32-36
[58]何浩,张玉亮,李海梅.胖子减肥胶囊治疗单纯性肥胖症的临床观察(J).第一军医大学学报,1999,19(4):44-45
[59]张淑亭,宋福生,李玉英等.降脂减肥健美饮治疗高脂肥胖症18例观察(J).河北中医,1994,16(4):12-13
[60]日本原桃介.肥胖症的汉方治疗(J).国外医学.中医中药分册1994,15(2):96-97
[61]朴联友,刘颖,张学丽.飞腾八法治疗单纯性肥胖(J).中国中医药讯息杂志,2002,9(7):5
[62]刘志诚,孙风岷,胡葵.针灸为主治疗单纯性肥胖患者的临床研究(J).上海针灸杂志,1997,16(1):6-8
[63]阙方旭,任爱华.扶元温肾法治疗单纯性肥胖症54例(J).中国民间疗法,1998,6(6):5
[64]李春生,陈可冀,冯晋光等.消补减肥片治疗老年单纯性肥胖病的研究(J).光明中医杂志,1994,9(3):18-20
[65]张文学.消胖丸治疗单纯性肥胖症286例临床观察(J).中医函授通讯,1999,18(2):21-22
[66]翁维良.中医治疗单纯性肥胖44例疗效观察(J).中医杂志,1988,40(1):29。
[67]孙庆培.肥胖症的中医治疗概况(J).中医杂志,1990.(5):53
[68]孟丽娟,孟鶱鹏,高秀丽.电针辨证治疗女性单纯性肥胖180例(J).中国临床康复,2002,6(23):35-36
[69]王红玉.针刺治疗单纯性肥胖病60例临床疗效观察.针灸临床杂志,2001,17(4):27-28
[70]张忠志,马峰峻,马野.耳针治疗418例单纯肥胖的效果观察(J).黑龙江医药 科学,2001,24(4):75-76
[71]Wozniak P,Oszukowski P,Stachowiak G,et al.The Effectiveness of low-caloric Diet orDiet with ACupuncture Treatment in Obese peri-and post-menopausal[J].Women GinekoiPol,2003,74(2):102.
[72]顾悦善,郑学良,崔述贵等.王不留行耳压减肥473例临床观察.中医杂志,1988,29(4):12
[73]何玲,江婵娟耳穴贴压在临床减肥中的应用(J).陕西中医学院学报,2003,26(3):37-38
[74]曹春,马逸.穴位埋线治疗肥胖症24例临床观察(J).中国针灸,1995,2(增刊):137
[75]杨福霞.穴位埋线治疗单纯性肥胖症的临床研究(J).中国针灸,2005,25(4):237-239
[76]许姿妙.穴位埋线治疗肥胖症100例临床观察.中国针灸,2002,22(2):95-96
[77]王国明,李丽霞,宋永强等.穴位埋线治疗单纯性肥胖症60例疗效观察.中国针灸,2001,21(7):395-406
[78]邹秋英.针刺治疗肥胖症100例疗效观察.河北中医,2001,23(7):530-531
[79]曲惠卿.针刺对肥胖病患者肾上腺皮质功能及血脂含量的影响.中国针灸,1994,14(1):1-2
[80]高洪生.针刺治疗单纯性肥胖症68例.陕西中医,2000,21(5):223-224
[81]金传,杨金山.电针与推拿并用治疗单纯性肥胖的临床观察29例(J).中级药学报,2003,31(3):16
[82]Taubes G.AS Obesity Rates Rise,Experts Struggle to Explain Why.Science.1998;280:B67-B68.
[83]Jung RT,Obesity as a disease.Br.Med.Bull 1997;53:307-21.
[84]Bjointorp P.Obesity.The Lancet.1997;350(9075):423-426.
[85]Wilding J.Science,medicine and the furture:Obesity treatment.BMJ.1997;315(7114):997-1000.
[86]翁维良.肥胖病学.知音出版社.台北,1996:4-5。
[87]Zang Y.Positional cloning of the mouse obese gene and it human homologue.Nature 1994;372:425-431.
[88]Dhurandhar NV.Association of anovirus infection with human obesity.Obesity Research1997;5:464-469.
[89]Atkinson RL.Use of Drugs in the treatment of obesity.Annu.Rev.Nutr.1997;17:383-403.
[90]Halaas JL.Weight-reducing effects of the plasma protein encoded by the obese gene.Science 1995;269(5223):543-546.
[91]Steven BH,Andrew SG.Recombinant Leptin for Weight Loss in Obese and Lean Adults.JAMA 1999;282:1568-1575.
[92]张介宾.张氏类经.新文丰出版社,1984:462-463。
[93]任应秋.素问今译.启业书局.台北.,1988:495。
[94]任应秋.素问今译.启业书局.台北,1988:524。
[95]任应秋.素问今译.启业书局.台北,1988:85。
[96]张景岳.景岳全书.人民卫生出版社,1985:86-88。
[97]翁维良.肥胖冠心病人心功能观察.全国第三届肥胖病研究学术会议,1991:25-29
[98]朱震亨.丹溪心法要.山东科技技术出版社,1985:1-14
[99]翁维良.实用中西结合肥胖病学.知音出版社,台北,1990:11
[100]胡绍文.单纯性肥胖证的预防.北京中医,1994增刊:2。
[101]陈敏先.降脂减肥片治疗肥胖证之临床观察.上海中医药杂志,1992,(5)1:41
[102]耿新华.减肥灵治疗893例肥胖证疗效观察.北京中医,1994增刊:102
[103]贾宝鹏.北京市34000人肥胖病调查.北京中医,1994增刊:197
[104]喜多岛修也.防风通圣散,防己黄耆汤力.肥胖证12文寸节反影响.日本东洋医学会志,1993;43(5):63
[105]徐如唐译.防风通圣散减肥作用的基础研究(日).国外医学.中医中药分册,1995:17(3):33
[106]宫本尚.和治医药会志,1994,11(4):400
[107]河上征治.肥胖病汉方治疗.现代东洋医学,1994,15(4):22-25
[108]陆静译.针刺治疗肥胖之研究.国外医学.中医中药分册,1994;16(4):49
[109]戚东焰译.采取一种新型耳针治疗病理性肥胖(英).国外医学.中医中药分册,1993:15(1):53。
[110]Lei ZP.Treatment of 42 cases of obesity with acupuncture.Journal of Traditional ChineseMesicine.1998;8(2):125-126.
[111]Xu B,Fei JZ.Clinical observation of the weight-reducing effect ear acupuncture in 350cases of obesity.Journal of Traditional Chinese Mesicine.1985;5(2):87-88.
[112]Hung MH,Yang RC,Hu SH.Preliminary results of triple therapy for obesity.1996;20(9):830-836.
[113]Shafshak TS.Electroacupuncture & exercise in body weight reduction and theirapplication in rehabilitating with knee osteoarthritis.American Journal of CchineseMedicine.1995;23(1):15-25.
[114]李国达.针灸治疗肥胖症近十年状况.针灸临床杂志,2000;(6):51-53。
[115]Vogrluk VG,Uglanova TM,Vogrluk MV.Role of reflexotherapy in the complex treatmentof neuroendocrine obesity.Terapevticheskii Arkhiv.1985;57(10):97-100.
[116]刘建英译.电针刺激肥胖证影响之研究.国外医学.中医中药分册,1994;16(1):59
[117]刘志诚.针刺减肥与植物神经功能的关系.中国康复医学杂志,1989;4(6):30
[118]Shiraishi T,Onoe M,Kojima T,Sameshima Y.Effects of auricular stimulation on feedingrtatedhypothalamic neuronal activity in normal and obesity rats.Brin Research Bulletin.1995;36(2):141-8.
[119]Liu ZC,Sun FM,Li J.Study of the theraprutic effect of acupuncture onl 134 cases ofsimple obesity.Int J Clin Acup.1998;2(2):6-8.
[120]Liu Z.et al.The good effects of acupuncture on digestive function in the patients suffering from simple obesity with stomach-heat accumlation.The Second World Congress ofMedical Acupuncture & Natural Medicine;1991:88
[121]Faust S.For an updated acupuncture.Revue Medicale de Bruxelles.1998;19(4):A290-A295.
[122]Sun FM,Liu ZC.Effect of acupuncture on energy metabolism in simple obesity.Int J ClinAcup.1997;8(2):123-128.
[123]刘志诚.针刺减肥的临床观察及其降低脂肪的研究.中国康复医学杂志,1990;5(3):110。
[124]Sun FM,Liu ZC,et al.Effect of acupuncture weight reduction on water metabolism.Int J Clin Acup.1999;10(1):1-7。
[125]刘志诚,孙凤鸣,韩燕等.针刺治疗单纯性肥胖症的实验研究.针刺研究,1998;23(1):69-75。